Terapia hormonal de reemplazo y riesgo de cáncer ginecológico en mujeres en el climaterio. Revisión narrativa.
Saved in:
| Title: | Terapia hormonal de reemplazo y riesgo de cáncer ginecológico en mujeres en el climaterio. Revisión narrativa. |
|---|---|
| Alternate Title: | Use of hormone replacement therapy in climacteric and gynecological cancer risk. Narrative review. |
| Authors: | Cristina Arteaga-Gómez, Ana1 dr.zapatacaballero@outlook.com, Agustín Zapata-Caballero, Carlos1, Arellano-Eguiluz, Arturo2, Emmanuel Santoyo-Rosas, Sergio2, Melina Robellada-Zárate, Claudia3 |
| Source: | Ginecología y Obstetricia de México. jun2021, Vol. 89 Issue 6, p464-471. 8p. |
| Subjects: | HORMONE therapy, CLIMACTERIC, GYNECOLOGIC cancer, CERVICAL cancer, BREAST cancer, OVARIAN cancer, PROGESTATIONAL hormones, ESTROGEN |
| Abstract (English): | OBJECTIVE: To identify and update, through a literature review, the magnitude of the risk involved in hormone replacement therapy in the incidence and recurrence of breast, ovarian, endometrial and cervical cancer in climacteric women. In addition, to evaluate the relationship with the time and type of treatment indicated. MATERIALS AND METHODS: Retrospective study, literature search of studies published from 2010 to 2020 with oncologic outcomes associated with hormone replacement therapy. The search was conducted in PubMed and Google Scholar search engines. RESULTS: We found 5848 related articles and discarded 3828 because they were published before 2010. The abstracts of 2020 articles were reviewed and 1980 were eliminated for not meeting the inclusion criteria. The final review was performed with 40 articles. CONCLUSIONS: Based on what has been published, the evidence suggests that there is an increased risk of breast cancer in users of combined hormone replacement therapy; the greatest secondary risk is with progestins. For endometrial the risk is higher with estrogens alone. For ovarian cancer the evidence is not sufficient to guide practice. For cervical cancer, the evidence suggests that hormone therapy has no risk. The risks and benefits of hormone replacement therapy have considerable variations depending on the specific regimen and the individual circumstances of each patient. [ABSTRACT FROM AUTHOR] |
| Abstract (Spanish): | OBJETIVO: Identificar y actualizar, mediante una revisión bibliográfica, la magnitud del riesgo que implica la terapia hormonal de reemplazo en la incidencia y recurrencia del cáncer de mama, ovario, endometrio y cuello uterino en mujeres en el climaterio. Además, evaluar la relación con el tiempo y tipo de tratamiento indicado. MATERIALES Y MÉTODOS: Estudio retrospectivo, de búsqueda bibliográfica efectuada en ensayos publicados de 2010 a 2020 con desenlaces oncológicos asociados con la terapia de reemplazo hormonal. La búsqueda se llevó a cabo en las bases de datos PubMed y Google Scholar. RESULTADOS: Se encontraron 5848 artículos relacionados y se descartaron 3828 por haberse publicado antes del 2010. Se revisaron los resúmenes de 2020 artículos y se eliminaron 1980 por no cumplir con los criterios de inclusión. La revisión final se efectuó con 40 artículos. CONCLUSIONES: Con base en lo publicado, la evidencia sugiere que hay un aumento del riesgo de cáncer de mama en las usuarias de terapia hormonal de reemplazo combinada; el mayor riesgo secundario es con las progestinas. Para el endometrio el riesgo es mayor con estrógenos aislados. Para el cáncer de ovario la evidencia no es suficiente para guiar la práctica. Para el cáncer cervicouterino, la evidencia sugiere que la terapia hormonal no tiene riesgo. Los riesgos y beneficios de la terapia hormonal de reemplazo tienen variaciones considerables dependientes del régimen específico y las circunstancias individuales de cada paciente. [ABSTRACT FROM AUTHOR] |
| Copyright of Ginecología y Obstetricia de México is the property of Federacion Mexicana de Ginecologia y Obstetricia and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | MedicLatina |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: lth DbLabel: MedicLatina An: 150919779 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Terapia hormonal de reemplazo y riesgo de cáncer ginecológico en mujeres en el climaterio. Revisión narrativa. – Name: TitleAlt Label: Alternate Title Group: TiAlt Data: Use of hormone replacement therapy in climacteric and gynecological cancer risk. Narrative review. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Cristina+Arteaga-Gómez%2C+Ana%22">Cristina Arteaga-Gómez, Ana</searchLink><relatesTo>1</relatesTo><i> dr.zapatacaballero@outlook.com</i><br /><searchLink fieldCode="AR" term="%22Agustín+Zapata-Caballero%2C+Carlos%22">Agustín Zapata-Caballero, Carlos</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Arellano-Eguiluz%2C+Arturo%22">Arellano-Eguiluz, Arturo</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Emmanuel+Santoyo-Rosas%2C+Sergio%22">Emmanuel Santoyo-Rosas, Sergio</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Melina+Robellada-Zárate%2C+Claudia%22">Melina Robellada-Zárate, Claudia</searchLink><relatesTo>3</relatesTo> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Ginecología+y+Obstetricia+de+México%22">Ginecología y Obstetricia de México</searchLink>. jun2021, Vol. 89 Issue 6, p464-471. 8p. – Name: Subject Label: Subjects Group: Su Data: <searchLink fieldCode="DE" term="%22HORMONE+therapy%22">HORMONE therapy</searchLink><br /><searchLink fieldCode="DE" term="%22CLIMACTERIC%22">CLIMACTERIC</searchLink><br /><searchLink fieldCode="DE" term="%22GYNECOLOGIC+cancer%22">GYNECOLOGIC cancer</searchLink><br /><searchLink fieldCode="DE" term="%22CERVICAL+cancer%22">CERVICAL cancer</searchLink><br /><searchLink fieldCode="DE" term="%22BREAST+cancer%22">BREAST cancer</searchLink><br /><searchLink fieldCode="DE" term="%22OVARIAN+cancer%22">OVARIAN cancer</searchLink><br /><searchLink fieldCode="DE" term="%22PROGESTATIONAL+hormones%22">PROGESTATIONAL hormones</searchLink><br /><searchLink fieldCode="DE" term="%22ESTROGEN%22">ESTROGEN</searchLink> – Name: Abstract Label: Abstract (English) Group: Ab Data: OBJECTIVE: To identify and update, through a literature review, the magnitude of the risk involved in hormone replacement therapy in the incidence and recurrence of breast, ovarian, endometrial and cervical cancer in climacteric women. In addition, to evaluate the relationship with the time and type of treatment indicated. MATERIALS AND METHODS: Retrospective study, literature search of studies published from 2010 to 2020 with oncologic outcomes associated with hormone replacement therapy. The search was conducted in PubMed and Google Scholar search engines. RESULTS: We found 5848 related articles and discarded 3828 because they were published before 2010. The abstracts of 2020 articles were reviewed and 1980 were eliminated for not meeting the inclusion criteria. The final review was performed with 40 articles. CONCLUSIONS: Based on what has been published, the evidence suggests that there is an increased risk of breast cancer in users of combined hormone replacement therapy; the greatest secondary risk is with progestins. For endometrial the risk is higher with estrogens alone. For ovarian cancer the evidence is not sufficient to guide practice. For cervical cancer, the evidence suggests that hormone therapy has no risk. The risks and benefits of hormone replacement therapy have considerable variations depending on the specific regimen and the individual circumstances of each patient. [ABSTRACT FROM AUTHOR] – Name: Abstract Label: Abstract (Spanish) Group: Ab Data: OBJETIVO: Identificar y actualizar, mediante una revisión bibliográfica, la magnitud del riesgo que implica la terapia hormonal de reemplazo en la incidencia y recurrencia del cáncer de mama, ovario, endometrio y cuello uterino en mujeres en el climaterio. Además, evaluar la relación con el tiempo y tipo de tratamiento indicado. MATERIALES Y MÉTODOS: Estudio retrospectivo, de búsqueda bibliográfica efectuada en ensayos publicados de 2010 a 2020 con desenlaces oncológicos asociados con la terapia de reemplazo hormonal. La búsqueda se llevó a cabo en las bases de datos PubMed y Google Scholar. RESULTADOS: Se encontraron 5848 artículos relacionados y se descartaron 3828 por haberse publicado antes del 2010. Se revisaron los resúmenes de 2020 artículos y se eliminaron 1980 por no cumplir con los criterios de inclusión. La revisión final se efectuó con 40 artículos. CONCLUSIONES: Con base en lo publicado, la evidencia sugiere que hay un aumento del riesgo de cáncer de mama en las usuarias de terapia hormonal de reemplazo combinada; el mayor riesgo secundario es con las progestinas. Para el endometrio el riesgo es mayor con estrógenos aislados. Para el cáncer de ovario la evidencia no es suficiente para guiar la práctica. Para el cáncer cervicouterino, la evidencia sugiere que la terapia hormonal no tiene riesgo. Los riesgos y beneficios de la terapia hormonal de reemplazo tienen variaciones considerables dependientes del régimen específico y las circunstancias individuales de cada paciente. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of Ginecología y Obstetricia de México is the property of Federacion Mexicana de Ginecologia y Obstetricia and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=lth&AN=150919779 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.24245/gom.v89i6.5189 Languages: – Code: spa Text: Spanish PhysicalDescription: Pagination: PageCount: 8 StartPage: 464 Subjects: – SubjectFull: HORMONE therapy Type: general – SubjectFull: CLIMACTERIC Type: general – SubjectFull: GYNECOLOGIC cancer Type: general – SubjectFull: CERVICAL cancer Type: general – SubjectFull: BREAST cancer Type: general – SubjectFull: OVARIAN cancer Type: general – SubjectFull: PROGESTATIONAL hormones Type: general – SubjectFull: ESTROGEN Type: general Titles: – TitleFull: Terapia hormonal de reemplazo y riesgo de cáncer ginecológico en mujeres en el climaterio. Revisión narrativa. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Cristina Arteaga-Gómez, Ana – PersonEntity: Name: NameFull: Agustín Zapata-Caballero, Carlos – PersonEntity: Name: NameFull: Arellano-Eguiluz, Arturo – PersonEntity: Name: NameFull: Emmanuel Santoyo-Rosas, Sergio – PersonEntity: Name: NameFull: Melina Robellada-Zárate, Claudia IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 06 Text: jun2021 Type: published Y: 2021 Identifiers: – Type: issn-print Value: 03009041 Numbering: – Type: volume Value: 89 – Type: issue Value: 6 Titles: – TitleFull: Ginecología y Obstetricia de México Type: main |
| ResultId | 1 |
